A Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients With T3, T4 or Node-Positive Rectal Cancer Patients Who Completed Curative-Intent Treatment

Trial Profile

A Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients With T3, T4 or Node-Positive Rectal Cancer Patients Who Completed Curative-Intent Treatment

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 17 Aug 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.
    • 18 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top